Frontiers in endocrinology · 2026
DLL3 expression in neuroendocrine carcinomas: a comparative analysis across tumor origins.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Calabrese Chiara, Dellavalle Sofia, Spadazzi Chiara, Sable Beate, French Dorothy, Isse Kumiko, Sharma Khushboo, Laino Vincenzo, Fasano Roberto, Tumedei Maria Maddalena, Pieri Federica, Ranallo Nicoletta, Foca Flavia, De Vita Alessandro, Miserocchi Giacomo, Cocchi Claudia, Vanni Silvia, Gabellone Sofia, Cani Oneda, Sbanchi Giulia, Bongiovanni Alberto, Liverani Chiara
Аннотация
BACKGROUND: Neuroendocrine carcinomas (NECs) are rare and highly aggressive tumors, characterized by a dismal prognosis. Their underlying biology remains insufficiently understood, highlighting an urgent need for the identification of disease markers to enhance diagnostic and prognostic assessments, as well as to identify potential druggable targets. DLL3, an inhibitory regulator of the Notch signalling pathway, has emerged as a promising candidate in this context.
METHODS: We investigated DLL3 prevalence and pattern of expression in immunohistochemistry in NECs from multiple anatomical sites, with a focus on lung and gastroenteropancreatic (GEP) neoplasms.
RESULTS: DLL3 was found to be highly expressed in 68.8% of NECs overall, with the highest prevalence observed in GEP-NECs (85.7%). Immunohistochemical analysis revealed predominantly cytoplasmic localization, with a dot-like staining pattern particularly evident in gastrointestinal cases, suggestive of potential localization in neurosecretory granules. DLL3 levels did not significantly correlate with tumor proliferation index nor with overall survival. A correlation with chromogranin A expression was found.
CONCLUSIONS: Given its high prevalence in extrapulmonary NECs, particularly those of GEP origin, it may have potential as a disease marker and therapeutic target in a clinical context where effective options are currently limited.
METHODS: We investigated DLL3 prevalence and pattern of expression in immunohistochemistry in NECs from multiple anatomical sites, with a focus on lung and gastroenteropancreatic (GEP) neoplasms.
RESULTS: DLL3 was found to be highly expressed in 68.8% of NECs overall, with the highest prevalence observed in GEP-NECs (85.7%). Immunohistochemical analysis revealed predominantly cytoplasmic localization, with a dot-like staining pattern particularly evident in gastrointestinal cases, suggestive of potential localization in neurosecretory granules. DLL3 levels did not significantly correlate with tumor proliferation index nor with overall survival. A correlation with chromogranin A expression was found.
CONCLUSIONS: Given its high prevalence in extrapulmonary NECs, particularly those of GEP origin, it may have potential as a disease marker and therapeutic target in a clinical context where effective options are currently limited.